EGFR and non-small cell lung carcinoma: Among patients with wildtype EGFR NSCLC, no patients with stage 1A received adjuvant platinum doublet chemotherapy, which increased to 6 of 65 patients (9.2%) with stage IB, 35 of 79 patients (44.3%) with stage II, and 27 of 51 patients (52.9%) with stage IIIA.